Navigation Links
CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
Date:10/28/2008

INDIANAPOLIS, Oct. 28 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced today that it has appointed Linda Hogan as Vice President of Business Development. In this position, Hogan will apply more than 25 years of experience in the pharmaceutical and biopharmaceutical industries to drive CoLucid's business development strategies. She will lead partnering initiatives and transactions for the company's rapidly advancing pipeline of compounds for the treatment of central nervous system (CNS) disorders.

Hogan continues to serve as an Executive in Residence at Care Capital, LLC where she assists with the sourcing and evaluation of potential investment opportunities, including the formation of new companies, and provides business development support to portfolio companies. She previously served as Vice President of Business Development with Clearview Projects, Inc. and was Vice President of Business Development at Aventis. Hogan received an MBA from Rockhurst College and an MS in Hospital Pharmacy at the University of Kansas School of Pharmacy.

The company also announced that Nadia Rupniak has been promoted to Vice President of Research and Development, where she will lead the advancement of the company's late-stage and preclinical therapeutic candidates.

Rupniak has more than 20 years of experience in the pharmaceutical industry, including more than two years with CoLucid. She previously held positions at Merck and at Dynogen Pharmaceuticals, Inc, where she served as the head of technology transfer.

"We are building and adding to our team to support the continued advancement of COL-144 for the acute treatment of migraine and our other drug candidates," said James White, CEO of CoLucid Pharmaceuticals. "We congratulate Nadia Rupniak on her promotion, which reflects the important contributions she has made in helping CoLucid meet our clini
'/>"/>

SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound
2. Anadys Pharmaceuticals to Present at Bio Investor Forum
3. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
4. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
5. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
6. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
7. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
8. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
9. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
10. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
11. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... XenaCare Holdings has announced that it has bec..., one of the largest nonprofit organizations dedic...tion. , Delray Beach, FL ...c. (OTCBB: XCHO), a company specializing in the ma...care products, has announced today that is has bec...
(Date:11/27/2009)... Multi-purpose bilingual coloring books designed...e business community to educate - inform parents a...fety issues to Dinosuars to ABC,S and a host of ot..., MO (PRWEB) November 27, 2009 -- Today’s ch... keep them busy any hour of the day, but one of th...
(Date:11/26/2009)... the number of Americans living with diabetes will...09 to 44.1 million in 2034. Over the same period, ...om $113 billion to $336 billion, even with no incr...ed at the University of Chicago report in the Dece...hose with diabetes covered by Medicare will rise f...
(Date:11/26/2009)... Dr. David Kim of the Live Life Again Center, a ... is one of a growing number of physicians who are ...es to connect with individuals who are interested ...obesity. Dr. Kim is utilizing Facebook to share be...actice with the community. , ...
(Date:11/25/2009)...Nov.25/PRNewswire/--TheBartleHallConventionCenterw...conDec.9-10,whenKansasCityhoststhelatestinaserieso...freecliniceventhasthepotentialtobethebiggestoneyet...beheldonweekdaysinsteadofoveraweekend,"SheriWood,e...presidentoftheNationalAssociationofFreeClinics(NAF...
Breaking Medicine News(10 mins):Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Kansas City Prepares for Largest Free Health Clinic 2
... INVESTMENT WILL SUPPORT AMERICA,S NEW GENERATION ...nal,Alliance for Hispanic Health (the Alliance) an...rck Ciencia Scholars Program, a new,partnership im...ugh a $4 million grant from The Merck Company Foun...
...es pioneering research with counselors June 6; pro...o a Ph.D. with the,last name of "Trotter," there i...uding a horse can be more beneficial than traditio...nseling (EPIC) Training June 6 at Bridlewood Stabl...
...ine, May 22 Nyer Medical Group,Inc. (Nasdaq: NYE...al year,2008. Revenues for the three months ended ...$18.92 million from $17.38 million as reported for...$.02,per share for the same period ended March 31,...
..., 2008 Hilton New Orleans Riv...es - Early-Bird Registration Sweep... Hours - Sponsorship ...e ADA 22nd New Dentist Conference: Jazzed in New O...
... of Rochester Reports SPY Accurately Detects Renal...R, TORONTO, May 22 /PRNewswire-FirstCall/ - Novad... real-time imaging and image guidance systems for,...he recent 2008 American Urological Association (AU...
...uity backed holding company enters into agreement ... MedQuist, MOUNT LAUREL, N.J., May 22 MedQuist I...er today Koninklijke Philips,Electronics N.V. (Phi...BaySystems Holdings Ltd., a publicly traded, AIM,l...
Other Medicine News:Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 2Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 3Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 4Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 5Health News:Equine Partners in Counseling (EPIC) Training Is Changing the Face of Mental Health 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.9 Million With Net Loss of $.16 Per Share for 3rd Quarter of Fiscal Year 2008 2Health News:Nyer Medical Group, Inc. Reports Revenues of $18.9 Million With Net Loss of $.16 Per Share for 3rd Quarter of Fiscal Year 2008 3Health News:Video: ADA 22nd New Dentist Conference: Jazzed in New Orleans 2Health News:Video: ADA 22nd New Dentist Conference: Jazzed in New Orleans 3Health News:Novadaq's SPY System was Topic of Best Poster in Scientific Session at AUA 2Health News:Novadaq's SPY System was Topic of Best Poster in Scientific Session at AUA 3Health News:MedQuist to Get New Majority Stakeholder 2Health News:MedQuist to Get New Majority Stakeholder 3Health News:MedQuist to Get New Majority Stakeholder 4
(Date:11/25/2009)...,Fla.,Nov.25/PRNewswire-FirstCall/--Formanyofthemi...llionlivingwithuntreated hearingloss ,theholidaysm..., Dr.Beyer,seniorvicepresidentofHearUSA(Amex: EAR... companies,saidstudieshavelinkedhearinglosstostres...intensifiedatholidaygatheringswithfamiliesandfrien...
(Date:11/25/2009)...5/PRNewswire/--Reportlinker.comannouncesthatanewma... UnitedStatesDentalDevicesMarketAnalysisandForeca...8733/United-States-Dental-Devices-Market-Analysis-...alDevicesMarketAnalysisandForecaststo2015 ,, S...epthinformationanddatarelatingtotheUSdentaldevices...
(Date:11/25/2009)...25/PRNewswire-FirstCall/--NuVasive,Inc.(Nasdaq: NU...ctsforminimallydisruptivesurgicaltreatmentsforthes...Monday,November30,2009,at5:30p.m.ET/2:30p.m.PT.The...imbursementfortheCompany,sproductsandwillincludeco...wersession.Thedial-innumbersare1-877-407-4018fordo...
Breaking Medicine Technology:For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Baylor Dallas Opens Nations First Neurosurgical OR Suite Featuring BrainSUITE iMRI GE Healthcare MR Surgical Technology 48035 1Baylor Dallas Opens Nations First Neurosurgical OR Suite Featuring BrainSUITE iMRI GE Healthcare MR Surgical Technology 48035 2Bart Peterson to Join Lilly Leadership Team 48032 1Bart Peterson to Join Lilly Leadership Team 48032 2Bart Peterson to Join Lilly Leadership Team 48032 3Low T Specialist reNEW MAN Promotes National Network of Doctors 48028 1Low T Specialist reNEW MAN Promotes National Network of Doctors 48028 2Low T Specialist reNEW MAN Promotes National Network of Doctors 48028 3Low T Specialist reNEW MAN Promotes National Network of Doctors 48028 4
...Eastern Time - , , SOUTH SAN FRANCISCO, Calif., ... PARD ), a biopharmaceutical company focused on on...ourth quarter and year ended December 31, 2008, an...ourth quarter of 2008, we made significant progres...ncology platform compound by advancing our pivotal...
...orporation (Nasdaq: DRRX ) announced today posit...rial conducted by Endo Pharmaceuticals of TRANSDUR...er development for the treatment of chronic pain. ...s reviewed with the U.S. Food and Drug Administrat...ing with the FDA on February 19, 2009. As a resul...
Other Medicine Technology:Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 9DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 2DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 3DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 4DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 5
...LifeWatch®, Inc. has been providing excellence...t thousands of physicians in the diagnosis and tre...ditions each year. State-of-the-art equipment and ...st standard of customer service makes LifeWatch th...
...Biomedical Systems' Cardiology Services division p...physicians' offices, hospitals, clinics, and unive...round-the-clock service and support, we customize ... our clients. Your office benefits: Caregivers rel...
...AerotelNet.com is an e-health service developed by...onitoring devices. Designed as a complementary tu...erotelNet.com improves patient and physicians medi...nced communication capabilities make it easy for p...
...The THERMOstar is a high performance temperature c...lates. Temperature, shaking speed and incubation t... status parameters are displayed on the LCD in rea...bove and below the microplates provide uniform inc...
Medicine Products: